廣生堂(300436.SZ)半年度預虧1600萬-1800萬元
格隆匯7月14日丨廣生堂(300436.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨虧損1600萬元-1800萬元,上年同期盈利1137.17萬元;扣除非經常性損益後的淨虧損2250萬元-2450萬元。
報吿期內,公司營業收入同比基本持平,淨利潤出現虧損,主要原因如下:1、報吿期內,公司積極推進c-Met靶向新藥GST-HG161和乙肝治療新藥GST-HG141、GST-HG131的I期臨牀研究,研發費用較上年同期增加約1,000萬元,同比大幅增長約50%;
2、報吿期內,公司有效拓展豐富了產品管線,新獲批恩替卡韋片、丙酚替諾福韋片、西地那非片(勁哥)、利伐沙班片和匹伐他汀鈣片,並組建了肝病事業部、心血管事業部、OTC事業部等,不斷加強營銷團隊建設和專業化學術推廣,銷售費用同比增加,新產品預計將在下半年貢獻營收;
3、上年末,公司總部大樓等陸續交付使用,報吿期內,折舊等費用較上年同期增加,同時公司為推進原料藥製劑一體化生產基地建設項目,人員招聘使得職工薪酬支出相應增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.